Skip to main content

Advertisement

SpringerLink
Log in

Bone

Use of bisphosphonates in children—proceed with caution

  • News & Views
  • Published:

From Nature Reviews Endocrinology

View current issue Sign up to alerts

A clinical review of studies on bisphosphonate therapy for pediatric osteoporosis has revealed that they increase BMD, but whether they also improve fracture rates or functions of daily life is unclear. Can the findings of this clinical review help inform clinicians whether, when and how to use these agents in children?

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

References

  1. Bachrach, L. K. & Ward, L. M. Clinical review: bisphosphonate use in childhood osteoporosis. J. Clin. Endocrinol. Metab. 94, 400–409 (2009).

    Article  CAS  Google Scholar 

  2. Letocha, A. D. et al. Controlled trial of pamidronate in children with types III and IV osteogenesis imperfecta confirms vertebral gains but not short-term functional improvement. J. Bone Miner. Res. 20, 977–986 (2005).

    Article  CAS  Google Scholar 

  3. Marini, J. C. Should children with osteogenesis imperfecta be treated with bisphosphonates? Nat. Clin. Pract. Endocrinol. Metab. 2, 14–15 (2006).

    Article  Google Scholar 

  4. Rauch, F., Travers, R. & Glorieux, F. H. Pamidronate in children with osteogenesis imperfecta: histomorphometric effects of long-term therapy. J. Clin. Endocrinol. Metab. 91, 511–616 (2006).

    Article  CAS  Google Scholar 

  5. Uveges, T. E. et al. Alendronate treatment of Brtl osteogenesis imperfecta mouse improves femoral geometry and load response before fracture but decreases predicted material properties and has detrimental effects on osteoblasts and bone formation. J. Bone Miner. Res. [doi:10.1359/jbmr.081238] (2008).

  6. Li, J. S. et al. Economic return of clinical trials performed under the pediatric exclusivity program. JAMA 297, 480–488 (2007).

    Article  CAS  Google Scholar 

  7. Whyte, M. P., Wenkert, D., Clements, K. L., McAlister, W. H. & Mumm, S. Bisphosphonate-induced osteopetrosis. N. Engl. J. Med. 349, 457–463 (2003).

    Article  CAS  Google Scholar 

  8. Whyte, M. P. et al. Bisphosphonate-induced osteopetrosis: novel bone modeling defects, metaphyseal osteopenia, and osteosclerosis fractures after drug exposure ceases. J. Bone Miner. Res. 23, 1698–1707 (2008).

    Article  Google Scholar 

  9. Allen, M. R. & Burr, D. B. Three years of alendronate treatment results in similar levels of vertebral microdamage as after one year of treatment. J. Bone Miner. Res. 22, 1759–1765 (2007).

    Article  CAS  Google Scholar 

  10. Weinstein, R. S., Robertson, P. K. & Manolagas, S. C. Giant osteoclast formation and long-term oral bisphosphonate therapy. N. Engl. J. Med. 360, 53–62 (2009).

    Article  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Bone and Extracellular Matrix Branch, National Institute of Child Health and Human Development, National Institute of Health, Bethesda, MD, USA

    Joan C. Marini

Authors
  1. Joan C. Marini
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Joan C. Marini.

Ethics declarations

Competing interests

The author declares no competing financial interests.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Marini, J. Use of bisphosphonates in children—proceed with caution. Nat Rev Endocrinol 5, 241–243 (2009). https://doi.org/10.1038/nrendo.2009.58

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1038/nrendo.2009.58

  • Springer Nature Limited

This article is cited by

Search

Navigation